Objectives: To investigate the effectiveness of biofeedback therapy for adult patients with primary monosymptomatic enuresis (MsE).
Material and Methods: In this prospective design study, the adult patients with primary MsE were included in the study. Patients with neuropathic bladder, daytime voiding problems, anatomical pathology and enuresis-related other diseases were excluded from the study. The de-mographic data of 13 adult patients who meet-ing the criteria were recorded. The outcomes of enuresis frequency, uroflowmetry parameters, post-void residual urine (PVR) and total blad-der volume (TBV) (voided volume + PVR) were evaluated before and at the end of the three month after biofeedback treatment. One or less enuretic night in a month was defined as the suc-cess of the biofeedback therapy.
Results: Including 6 men and 7 women, the mean age of 13 patients was 29.2 ± 8.2 years. Before biofeedback therapy the incidence of en-uresis was 23.4 ± 5.9 (monthly), while after treat-ment this was calculated as 5.2 ± 8.9 (p=0.002). There was no significant difference found be-tween before and after biofeedback therapy in terms of PVR, maximum flow rate (Qm) and av-erage flow rate (Qa). The mean TBV of patients increased from 277.8 ml to 329.9 ml after bio-feedback treatment (p=0.001).
Conclusion: Biofeedback therapy is a safe, simple and minimally invasive treatment mo-dality in adult patients with primary MsE. This treatment, which was found to increase TBV, may be recommended for this special patient group.
Keywords: adult enuresis, biofeedback, bladder capacity, monosymptomatic enuresis, uroflowmetry.
Abstract
Objectives: To investigate the effectiveness of biofeedback therapy for adult patients with primary monosymptomatic enuresis (MsE).
Material and Methods: In this prospective design study, the adult patients with primary MsE were included in the study. Patients with neuropathic bladder, daytime voiding problems, anatomical pathology and enuresis-related other diseases were excluded from the study. The de-mographic data of 13 adult patients who meet-ing the criteria were recorded. The outcomes of enuresis frequency, uroflowmetry parameters, post-void residual urine (PVR) and total blad-der volume (TBV) (voided volume + PVR) were evaluated before and at the end of the three month after biofeedback treatment. One or less enuretic night in a month was defined as the suc-cess of the biofeedback therapy.
Results: Including 6 men and 7 women, the mean age of 13 patients was 29.2 ± 8.2 years. Before biofeedback therapy the incidence of en-uresis was 23.4 ± 5.9 (monthly), while after treat-ment this was calculated as 5.2 ± 8.9 (p=0.002). There was no significant difference found be-tween before and after biofeedback therapy in terms of PVR, maximum flow rate (Qm) and av-erage flow rate (Qa). The mean TBV of patients increased from 277.8 ml to 329.9 ml after bio-feedback treatment (p=0.001).
Conclusion: Biofeedback therapy is a safe, simple and minimally invasive treatment mo-dality in adult patients with primary MsE. This treatment, which was found to increase TBV, may be recommended for this special patient group.
Keywords: adult enuresis, biofeedback, bladder capacity, monosymptomatic enuresis, uroflowmetry.